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Abstract
Purpose—To compare the risks of radiogenic second cancers and cardiac mortality in 17
pediatric medulloblastoma patients treated with passively scattered proton or field-in-field photon
craniospinal irradiation (CSI).
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Material/ methods—Standard of care photon or proton CSI treatment plans were created for all
17 patients in a commercial treatment planning system (TPS) (Eclipse version 8.9; Varian Medical
Systems, Palo Alto, CA) and prescription dose was 23.4 Gy or 23.4 Gy(RBE) to the age specific
target volume at 1.8 Gy/fraction. The therapeutic doses from proton and photon CSI plans were
estimated from TPS. Stray radiation doses were determined from Monte Carlo simulations for
proton CSI and from measurements and TPS for photon CSI. The Biological Effects of Ionization
Radiation VII report and a linear model based on childhood cancer survivor data were used for
risk predictions of second cancer and cardiac mortality, respectively.
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Results—The ratios of lifetime attributable risk (RLARs) (proton/photon) ranged from 0.10 to
0.22 for second cancer incidence and ranged from 0.20 to 0.53 for second cancer mortality,
respectively. The ratio of relative risk (RRR) (proton/photon) of cardiac mortality ranged from
0.12 to 0.24. The RLARs of both cancer incidence and mortality decreased with patient's age at
exposure (e), while the RRRs of cardiac mortality increased with e. Girls had a significantly higher
RLAR of cancer mortality than boys.
Conclusion—Passively scattered proton CSI provides superior predicted outcomes confers
lower predicted risks of a second cancer and cardiac mortality than field-in-field photon CSI for
all medulloblastoma patients in a large clinically representative sample in the United States, but
the magnitude of superiority depend strongly on the patients' anatomical development status.
Keywords
Medulloblastoma; craniospinal irradiation; proton therapy; second cancer; cardiac mortality
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Improvements in pediatric cancer patients treatment outcomes have been clearly
demonstrated, including longer mean survival time compared with previous treatment eras
[1,2]. Radiation therapy has long been recognized as an effective treatment for many cancers
in children. However, radiogenic side effects, which include second cancers, cardiac
toxicity, pulmonary toxicity, and impaired growth and bone development [3,4], may reduce
survivors' lifespan and quality of life.
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Second cancers account for around 16% of all cancers and solid tumors comprise a leading
cause of mortality among cancer survivors in the United States [5]. For some pediatric
cancers, treatment-induced second cancers can cause more deaths than the primary cancers
do [6]. The Childhood Cancer Survivor Study (CCSS), which included a large cohort of
cancer patients who have survived more than five years, reported that the mortality rate
attributable to recurrence or progression of primary cancers in children is decreasing while
the mortality rates attributable to subsequent neoplasms and to cardiac and pulmonary
toxicity from treatment are increasing [7]. CCSS also found that the risk of cardiovascular
disease was substantially higher in cancer survivors than in the general population [7-9] and
that cardiovascular events are the leading non-malignant cause of death among survivors of
childhood cancer [10].
The risks of radiogenic second cancer or cardiac toxicity have been studied [11-15], but few
of those studies compared photon and proton radiation therapies in a large sample set of
patients. The aim of this work was to predict and compare the risks of radiogenic second
cancers and cardiac mortality in a representative sample of pediatric patients with
medulloblastoma (MB) treated using photon craniospinal irradiation (CSI) versus proton
CSI. Both therapeutic and secondary radiation doses were included in the risk calculations.
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Patient selection
Pediatric patients diagnosed with MB and treated with proton radiation therapy at The
University of Texas MD Anderson Cancer Center (UT MDACC) in 2007–2009 were
selected for this study We followed a retrospective data analysis protocol approved by our
institutional review board. Inclusion criteria were an age at exposure of 2–18 years,
treatment in the supine position and available computed tomography (CT) images.
Seventeen MB patients were included: 10 who were 2 to 10 years old and 7 who were 11 to
18 years old. Among them 8 were females and 9 were males. The patients were selected to
represent a general population of children and adolescents who received radiation therapy
for MB; our sample included males and females whose ages, heights, and weights spanned a
clinically relevant and representative spectrum (age 2 to 18 years, height 85 to 173 cm, body
mass index (BMI) 16.4 to 37.9 kg/m2).
Treatment techniques and organs of interest
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Proton and photon treatment plans were both retrospectively created using a commercial
TPS (Eclipse version 8.9; Varian Medical Systems, Palo Alto, CA). The proton treatment
plans were designed to treat the patient using the passively scattered proton beam line at UT
MDACC proton therapy center. For both plans, an age-specific target volume was defined
for each patient. This volume included the brain, the spinal canal, and the entire vertebral
body for patients younger than 15 years (to prevent bone growth deformity due to nonuniform dose distribution in the vertebral body), and only the brain and spinal canal for
patients 15 years old or older (with a 2–3 mm margin anteriorly). Typical target volumes for
representative patients were shown in previous reports [16,17]. The proton treatment plans
included right and left posterior oblique cranial fields and 1–3 posterior-anterior spinal
fields, depending on the length of the patient's spinal axis. The photon treatment plans
contained 2 opposed lateral cranial fields and 1 or 2 posterior-anterior spinal fields,
depending on the length of the spinal axis. All photon fields were 6 MV, and a field-in-field
technique was used to improve the dose uniformity across the target volume. The treatment
plans were designed to deliver 23.4 Gy (relative biological effectiveness [RBE]) (proton
beam RBE of 1.1 was used here [18]) for proton CSI or 23.4 Gy for photon CSI to the age
specific target volume at 1.8 Gy/fraction. Additional details about the proton and photon
radiation therapy plans and typical isodose distributions for representative patients can be
found in previous reports [16,17].
The organs of interest for radiogenic second cancer risk estimation included the stomach,
colon, lungs, breasts, bladder, thyroid, liver, prostate, and remainder (i.e., the organs and
tissues for which risk coefficients were not provided in the Biological Effects of Ionizing
Radiation [BEIR] VII report [19]). These organs as well as each patient's heart were
contoured for this study in their entirety within the extent of the CT images. The ovaries
were not included in our risk analysis because their position is highly variable and they are
not readily visible on CT images [20]. The external surface of the heart was contoured in
every CT slice from the inferior border of the right pulmonary artery to the apex of the heart.
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Dose reconstruction and risk calculation
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The therapeutic doses from the proton and photon treatment plans were estimated from TPS
directly. The stray dose from proton therapy was calculated by our Monte Carlo Proton
Radiotherapy Treatment Planning system [11], which uses the Monte Carlo N-particle
eXtended code (version 2.6; Los Alamos National Laboratory, Los Alamos, NM) [21] as a
dose calculation engine. The secondary dose from photon therapy was obtained from the
TPS and measurement [22]. Our method was previously described in the literature [23,24]
and briefly summarized here: For organs in close proximity to the treatment field, doses are
accurately reported by the TPS and as such doses were directly taken from the TPS. For
organs far from the treatment field, TPS data were supplemented using analytical model
based on measurements in an anthropomorphic phantom. The equivalent dose in each organ,
HT, was calculated by multiplying mean organ dose, DT, by the radiation weight factor,
.
For stray neutrons in proton CSI,
values were taken from a separate CSI study by
Newhauser et al. [11].
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Lifetime attributable risk (LAR) was defined in BEIR VII as the probability of cancer
incidence or mortality during one's lifetime (living to 100 years) after exposure to a certain
equivalent dose (HT) at age at exposure, e. For each modality, the total LAR was calculated
as follows:

(1)

where the sum is over all the organs of interest. To compare the risks of proton and photon
therapies, the ratio of LARs (RLAR) between the two modalities was defined as follows:

(2)

where the subscripts h and p denote proton therapy and photon therapy, respectively More
details of the risk calculation for second cancers can be found in Zhang et al. [14].
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Tukenova et al. [25] recently reported a linear relationship between the mean radiation dose
to the heart and the relative risk of cardiac mortality based on follow-up data from a large
sample of childhood cancer survivors:

(3)

where RR is the relative risk; H is the mean heart equivalent dose; and α1, the linear
coefficient, is 0.6 (95% confidence interval, 0.2–2.5). The ratio of relative risk (RRR) of
cardiac mortality was defined as

(4)

the subscript h, p denotes proton therapy and photon therapy, respectively.
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Statistical analysis
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A two-sided linear correlation was used to test for significant correlations between
calculated values of RLAR, RR, RRR and patients' age at exposure. The two-sample twosided t-test was used to test differences between sexes. A p value of less than 0.05 indicates
a significant correlation or a significant difference in these tests. All statistical analyses were
performed with MATLAB (Mathworks, Natick, MA).

Results
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Table 1 lists the mean primary organ doses in current study and those from Mu et al. [12].
Except in lung, proton plans resulted in much lower organ doses than photon plans. The
stray radiation dose is also an important component of a full comparison of different
radiotherapy modalities, especially when late effects like second cancer and cardiac toxicity
are considered. Table 1 also lists the mean stray neutron doses by organ from the proton
plans. Owing to the methodology we used to calculate photon dose, it was not possible to
separate the stray (secondary) dose from the therapeutic dose for photon plans. Specifically,
the treatment planning algorithm does not distinguish between primary, scattered, and
leakage photons.
Table 2 and 3 (supplemental material) show the organ-specific LAR values of cancer
incidence and mortality (i.e., a fatal radiation-induced cancer) after proton or photon CSI for
the sample of patients. The predominant cancer risks were from lung and remainder for both
cancer incidence and mortality. Photon CSI confers much higher risks to all the organs for
all the patients.
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Fig. 1 shows the RLAR of second cancer incidence and mortality for the sample of patients
as a function of patient age at exposure (e). The RLARs were less than 1 for each patient,
regardless of e and sex, which means proton therapy conferred significantly lower risks of
cancer incidence and mortality than photon therapy (p ≪ 0.001 for both). The RLARs
ranged from 0.10 to 0.22 for second cancer incidence and ranged from 0.20 to 0.53 for
second cancer mortality, respectively. There was a significant correlation between
predicated RLAR of cancer incidence and e (correlation coefficient r = −0.74; p < 0.001),
and RLAR of second cancer mortality and e were weakly correlated (r = −0.44; p = 0.075).
The predicted RLAR of second cancer incidence was independent of sex (t test, p = 0.29),
but interestingly, the predicted RLAR of second cancer mortality was dependent on sex: girls
had a significantly higher RLAR of second cancer mortality than boys (t test, p = 0.023).
Fig. 2 shows the RR and RRR of cardiac mortality for this sample of patients as a function of
e. The RRRs of cardiac mortality ranged from 0.12 to 0.24. Proton therapy conferred
significantly lower risks of cardiac mortality than photon therapy (p < 0.001). There was no
significant correlation between predicated RR values and e for proton CSI (r = -0.18, p =
0.48), but there was a significant correlation between RR and e for photon CSI (r = -0.70, p
= 0.0019), and there was a significant correlation between RRR and e (r = 0.60, p = 0.01).
The predicted RR values were independent of sex (t test, p = 0.37 for proton CSI and p =
0.76 for photon CSI), and RRR values were independent of sex (t test, p = 0.55).
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Discussion
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We predicted risks of radiogenic second cancers and cardiac mortality after photon or proton
CSI for a sample of 17 pediatric patients with MB, considering both primary and stray
radiation doses. We found that proton CSI can reduce the predicted risks of radiogenic
second cancer incidence and cardiac mortality for these pediatric patients by 6 times, and
can reduce the predicted risk of second cancer mortality by 3 times, compared with
conventional photon CSI.
Considering that there are around 600 new MB cases each year in the United States [26],
that CSI is a mainstay of therapy [27], and a clinically representative sample used in this
work, our findings are of clinical significance because they show that proton CSI can
potentially confer much lower risks of late effects than photon CSI for all these MB patients
in the United States.
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RLARs of second cancer incidence and mortality decreased with increasing e, because the
target volume included the entire vertebral body for the younger patients but only the brain
and spinal canal for the older patients, and because normal tissues are further away from
treatment site in bigger patients. Although the proton and photon CSI plans both followed
these mechanisms, the inherent physical characteristic of proton beams (stop sharply after
target volume) results in a lower exit dose to normal tissues in the older patients than the
photon beams did. These indicated that older patients could benefit more from proton CSI in
terms of reducing predicted second cancer.
Girls had significantly higher RLARs of second cancer mortality than boys, partially because
the lung dose from proton CSI was significantly less than that from photon CSI for boys (p
= 0.015) but not for girls (p = 0.07). In fact, girls generally have smaller size than boys at the
same age, which means a larger portion of girl's lung was exposed to therapeutic radiation
and thus lung dose difference between proton and photon CSI was not that obvious.
Together with the facts that lung dose was higher than other organs (Table 1) and it has the
highest risk coefficient for second cancer mortality of any organ considered in this work
[19], the lung dose contributed to the girls' higher RLARs of second cancer mortality.
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The RR of cardiac mortality decreased with e after photon CSI but not after proton CSI. This
is because the heart dose was not affected substantially by patient size in proton CSI as in
photon CSI (in other words, there was almost no exit proton beam dose to the heart, even for
the young patients), so the risk after proton CSI did not decrease significantly with e (fig.
2(a)). This also explained why RRR values increased with e, and indicated younger patints
could benefit more from proton CSI in terms of reducing predicted cardiac mortality.
This study had a number of strengths. We included a larger cohort of MB patients than
previous studies did, with ages and sexes that are representative of a general pediatric
population in the United States. Because each treatment technique was based on the current
standard of care at a single institution, our results were clinically realistic. In addition, our
advanced dose reconstruction tools, including TPS, Monte Carlo simulation and phantom
measurements, enabled us to provide an accurate and comprehensive evaluation of radiation
doses.
Radiother Oncol. Author manuscript; available in PMC 2015 October 01.
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We can compare our dosimetric data with those of Mu et al. [12], who used conventional
photon therapy plans and intensity modulated proton therapy (IMPT) plans in a study of 5
pediatric MB patients. Because Mu et al. did not include stray radiation doses in their study,
we can compare only the therapeutic doses (Table 1). The two sets of dosimetric results
agree well, and both studies found that proton beams delivered a lower primary dose to all
the organs at risk than photon beams. Because Mu et al. used effective dose to estimate
second cancer risk, we cannot compare their risk estimates with ours directly.
Brodin et al. [13] compared various treatment techniques, including IMPT and 3D
conformal photon therapy, for 10 pediatric MB patients. Because they did not publish the
organ dose values and used different dose-risk models for second cancer and cardiac
mortality it is difficult to compare our results with theirs directly. However, we can compare
the ratios of lifetime risk of second cancer incidence: their mean ratio of risk between IMPT
and 3D conformal photon therapy was 0.16, which agrees well with our cohort's mean RLAR
of second cancer incidence after proton versus photon therapy (0.15 ± 0.04).
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Our study had some potential limitations. First, no consensus exists on which second cancer
dose-risk models should be used for organs that receive high doses. Some groups have
argued that the BEIR VII report was developed for low dose and low dose rate and proposed
alternative dose-risk models [28-31]. However, these new risk models are still under
development and may contain unknown large errors. We therefore decided to follow the
BEIR VII report and use ratios of risks instead of absolute risk values of second cancer
because several independent studies suggested the former to be a more robust measure for
comparing treatment modalities [13,14,32,33]. The good agreement of RLAR values
between Brodin et al. [13] and the present work provided more strong evidence that a ratio
of risks should be used for inter-institution comparisons. The second limitation is that we
only investigated a passively scattered proton CSI and field-in-field photon CSI in this work,
while other modalities like IMPT [13,34], IMRT [34,35], Tomotherapy [35,36] and
Volumetric Modulated Arc Therapy (VMAT) [37] are also used at some centers. However,
most of these advanced treatment modalities are not routinely used for CSI treatment,
whereas the techniques in our study are. Also, with respect to the photon treatment planning,
we used advanced conformal therapy, i.e., the field-in-field modulation technique to
minimize heterogeneities in the dose distributions. This had the effect of reducing the plan
hot spots and for the spine fields resulted in a marked decrease in the dose to organs anterior
to the spinal canal. So we don't consider this as a real limitation but strength because our
results are based on clinically realistic data and treatment plans. Another potential limitation
is that we estimated the RR of cardiac mortality only for the entire heart instead of
calculating risks for each heart sub-structure, e.g., myocardium and pericardium [38]. This
was because the literature did not specifically report any detailed relationship between dose
and outcome of cardiac mortality for individual heart sub-structures in MB patients, so
normal tissue complication probability (NTCP) model parameters were not available.
Considering the possible large uncertainties associated with NTCP calculations, we decided
for the purpose of this study that RR based on whole-heart dose and a linear risk model was
a more suitable metric.
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Conclusion
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We performed dose reconstructions and predictions of the risks of radiogenic second cancer
and cardiac mortality for a clinically representative sample of MB patients. The results
revealed that proton CSI can confer much lower predicted risks of late effects than photon
CSI. These findings strongly suggest proton therapy will provide better quality of life for
long-term survivors of pediatric MB..

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Ratio of lifetime absolute risk (RLAR) of radiogenic second cancer incidence or mortality
after proton versus photon CSI as a function of patient age at exposure, e, for a sample of
pediatric MB patients.

NIH-PA Author Manuscript
Radiother Oncol. Author manuscript; available in PMC 2015 October 01.

Zhang et al.

Page 12

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 2.

(a) Relative risk (RR) and (b) ratio of relative risk (RRR) of cardiac mortality after proton or
photon CSI as a function of patient age at exposure, e, for a sample of pediatric MB patients.
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3.4 ± 1.6

5.6 ± 1.5

5.1 ± 0.7

3.2 ± 0.8

10.4 ± 2.2

1.7 ± 0.6

0.9 ± 0.2

1.9 ± 1.1

15.3 ± 3.7

Colon

Liver

Lung

Heart

Breast

Prostate

Bladder

Thyroid

Photon

This work

0.1 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.2 ± 0.2

1.8 ± 0.9

0.2 ± 0.1

0.2 ± 0.2

0.1 ± 0.2

Proton

8.2 ± 6.3

-

-

0.3 ± 0.2

11.9 ± 0.9

3.0 ± 0.6

5.5 ± 0.4

-

4.1 ± 1.4

Photon

0.0 ± 0.0

-

-

0.0 ± 0.0

0.0 ± 0.0

2.2 ± 0.1

0.0 ± 0.0

-

0.1 ± 0.1

IMPT

Mu et al. (2005)

Mean therapeutic dose ± SD (Gy)

Stomach

Organ

42.3 ± 5.4

14.0 ± 4.3

5.6 ± 7.0

22.5 ± 1.1

27.8 ± 5.6

34.5 ± 6.0

25.2 ± 6.4

22.4 ± 4.9

26.2 ± 5.7

Mean stray neutron dose ± SD (cSv) from this work

Mean therapeutic doses ± standard deviation (SD) to organs of interest from photon and proton CSI plans in current study (N = 17) and study by Mu et al.
[12] (N = 5), and mean ± standard deviation (SD) of stray neutron doses to organs of interest from proton CSI plans in currentt study. Dashed table entries
indicate that the dose values were not available.
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M

M

M

M

M

M
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6

8

9

12

13
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3

4

6

8

9
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14

15

F

2

4

Sex

Age

172.1

162.5
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166.3

129.5

123.4

144.8

128
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162.5

147

146

130.6

142

115.2

111.7

85

Height (cm)

0.2, 1

0.3, 2

0.2, 2

0.4, 2

0.2,1

0.2, 6

0.6, 2

0.4, 2

0.4, 3

0.2, 3

0.3, 7

0.4, 4

0.4, 5

0.4, 5

0.5, 2

1, 5

0.3, 6

Stomach

1, 14

1, 23

1, 13

1, 23

3, 19

1, 18

2, 24

4, 28

1, 30

0.4, 6

0.8, 11

1, 9

1, 12

1, 16

1, 15

1, 20

1, 29

Colon

0.2, 2

0.3, 3

0.1, 3

0.4, 3

0.2, 3

0.2, 3

0.3, 4

0.3, 4

0.4, 5

0.1, 1

0.2, 1

0.1, 2

0.1, 1

0.2, 2

0.1, 2

0.2, 2

0.1, 2
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4, 6

4, 6

4, 7

5, 7

5, 9
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8, 13

14, 16

14, 19

5, 13

15, 23

13, 23

21, 23

12, 22

30, 32

27, 41

36, 44

Lung

0.1, 0.5

0.1, 1

0.1, 1

0.1, 1

0.1, 1

0.1, 1

0.2, 1

0.2, 1

0.2, 1

2, 6

2, 10

2, 14

3, 19

2, 21

3, 25

3, 32

4, 40

Breast/ prostate

0.3, 2

0.3, 2

0.1, 3

0.5, 6

0.3, 3

0.3, 4

0.4, 5

0.4, 8

0.7, 15

0.2, 1

0.3, 2

0.3, 3

0.3, 3

0.2, 3

0.4, 4

0.5, 8

0.4, 6

Bladder

LAR incidence (%) (proton, photon)

0.2, 10

0.3, 9

0.2, 11

0.3, 12

0.4, 12

0.4, 18

1, 14

1, 17

1, 14

1, 46

3, 52

1, 61

2., 84

2, 59

2, 87

3, 75

4, 68

Thyroid

2, 28

3, 31

2, 33

4, 39

4, 35

5, 52

6, 43

10, 58

10, 66

2, 28

5, 37

4, 39

6, 46

4, 42

8, 51

10, 66

12, 85

Remainder

Patient characteristics and organ-specific lifetime attributable risk (LAR) of cancer incidence after proton or photon CSI for a sample of pediatric MB
patients.
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6
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6
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Sex

Age

172.1

162.5
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166.3

129.5

123.4

144.8
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101

162.5
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146

130.6

142

115.2

111.7

85

Height (cm)

0.1, 0.5

0.2, 1

0.1, 1

0.2, 1

0.1, 1

0.1, 3

0.3, 1

0.2, 1

0.2, 2

0.1, 2

0.2, 4

0.2, 2

0.3, 3

0.2, 3

0.3, 1

0.7, 3

0.2, 3

Stomach

0.4, 7

0.5, 11

0.3, 6

0.6, 11

1.4, 9

0.5, 9

0.9, 12

2, 14

0.4, 14

0.2, 3

0.4, 5

0.5, 4

0.4, 5

0.4, 7

0.3, 7

0.6, 9

0.4, 13
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0.1, 2

0.2, 2

0.1, 2

0.3, 2

0.1, 2

0.2, 2

0.2, 3

0.3, 3

0.3, 3

0.1, 1

0.2, 1

0.1, 2

0.1, 1

0.1, 1

0.1, 2

0.1, 2

0.1, 2
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4, 6

4, 6

4, 7

5, 7

5, 9
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14, 19

4, 11

13, 20
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10, 19

26, 28

23, 36
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Lung

0.02, 0.1

0.02, 0.1

0.02, 0.2

0.02, 0.2

0.02, 0.2

0.02, 0.2

0.03, 0.2

0.03, 0.3

0.03, 0.2

0.4, 1

0.6, 2

0.5, 3

0.7, 4

0.6, 5

0.7, 6

0.8, 8

0.9, 9

Breast/ prostate

0.1, 0.4

0.1, 0.4

0.02, 1

0.1, 1

0.1, 1

0.1, 1

0.1, 1

0.1, 2

0.2, 3

0.1, 0.4

0.1, 0.4

0.1, 1

0.1, 1

0.1, 1

0.1, 1

0.1, 2

0.1, 2

Bladder

LAR mortality (%) (proton, photon)

1, 6
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1, 7

2, 10
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2, 12

2, 11

4, 15

4, 20
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2, 11

2, 11
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2, 13

3, 14

4, 20

5, 29

Remainder

Patient characteristics and organ-specific lifetime attributable risk (LAR) of cancer mortality after proton or photon CSI for a sample of pediatric MB
patients.
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